Literature DB >> 15809914

The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae.

Alun C Kirby1, John G Raynes, Paul M Kaye.   

Abstract

Tumor necrosis factor (TNF) has been proposed as a major mediator of host resistance in murine models of Streptococcus pneumoniae infection; in humans, anti-TNF therapies have been implicated in increased susceptibility to pneumococcal infection. Here, we use nonlethal (serotype 6B) and lethal (serotype 3) S. pneumoniae, neutralizing monoclonal antibodies to TNF, and TNF gene-deficient mice to reexamine the role played by TNF in antistreptococcal responses. After nonlethal challenge, primary resistance and all examined parameters of the cellular inflammatory response occurred independently of TNF activity. After lethal challenge, TNF deficiency resulted in more-rapid death but did not affect lung inflammation. However, the livers of the TNF gene-deficient mice, but not of the control mice, exhibited extensive signs of systemic disease. TNF, therefore, is dispensable for a complete cellular pulmonary inflammatory response to S. pneumoniae infection but enhances survival from disseminated lethal infection, at least in part by delaying systemic organ damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809914     DOI: 10.1086/429296

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Etanercept in chronic severe asthma.

Authors:  C Oliveri; R Polosa
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

2.  Interleukin-10 plays a key role in the modulation of neutrophils recruitment and lung inflammation during infection by Streptococcus pneumoniae.

Authors:  Hernán F Peñaloza; Pamela A Nieto; Natalia Muñoz-Durango; Francisco J Salazar-Echegarai; Javiera Torres; María J Parga; Manuel Alvarez-Lobos; Claudia A Riedel; Alexis M Kalergis; Susan M Bueno
Journal:  Immunology       Date:  2015-09       Impact factor: 7.397

Review 3.  Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses.

Authors:  Minny Bhatty; Stephen B Pruett; Edwin Swiatlo; Bindu Nanduri
Journal:  Alcohol       Date:  2011-09       Impact factor: 2.405

4.  A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

Authors:  Kevin Fabrizio; Abraham Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

5.  Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker.

Authors:  Christian Renaud; Philippe Ovetchkine; Patricia Bortolozzi; Claire Saint-Cyr; Bruce Tapiero
Journal:  Eur J Pediatr       Date:  2010-11-10       Impact factor: 3.183

6.  Pulmonary dendritic cells and alveolar macrophages are regulated by gammadelta T cells during the resolution of S. pneumoniae-induced inflammation.

Authors:  A C Kirby; D J Newton; S R Carding; P M Kaye
Journal:  J Pathol       Date:  2007-05       Impact factor: 7.996

7.  A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis.

Authors:  Raniyah T Ramadan; Andrea L Moyer; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-27       Impact factor: 4.799

8.  c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection.

Authors:  Abiodun D Ogunniyi; James C Paton; Alun C Kirby; Jonathan A McCullers; Jan Cook; Mamoru Hyodo; Yoshihiro Hayakawa; David K R Karaolis
Journal:  Vaccine       Date:  2008-07-18       Impact factor: 3.641

9.  Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.

Authors:  Daniela M Ferreira; Michelle Darrieux; Maria Leonor S Oliveira; Luciana C C Leite; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2008-01-09

Review 10.  Potential role for mucosally active vaccines against pneumococcal pneumonia.

Authors:  Kondwani C Jambo; Enoch Sepako; Robert S Heyderman; Stephen B Gordon
Journal:  Trends Microbiol       Date:  2009-12-22       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.